Acro Biomedical Co., Ltd. — Cyborg Score 2/10

Strategic Profile

The company engages in purchasing products from three suppliers in Taiwan and selling these products in bulk to companies who may use them as ingredients or resell them to their own customers. Operations remain minimal with significant liquidity challenges reflected in extremely low market capitalization and share price.

Cyborg Score Rationale

The company faces severe operational and financial headwinds. As of the latest data, the market cap is approximately $42,000, with only 1 employee as of March 26, 2026. Trading activity is minimal and the stock shows signs of distress.

Top Insights

• Highly specialized distribution model focused on cordyceps-based nutritional products sourced from Taiwan
• Extremely limited operational footprint with only 1 employee and minimal annual activity
• Trading on OTC markets with minimal liquidity and volume; stock price near negligible levels
• Company rebranded from Killer Waves Hawaii, Inc. to Acro Biomedical Co., Ltd. in January 2017

Named Competitors

• Cordyceps Products — Traditional Chinese medicine-based nutritional supplements

Open the full interactive Acro Biomedical Co., Ltd. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.